1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Antithrombotic Drugs: World Industry and Market Prospects 2015-2025

Treating thrombosis – new analysis showing trends, R&D and revenue forecasts
See the future of antithrombotic medicines. For those treatments you can now get new sales predictions, also exploring research and development. Discover business potentials. And assess results, trends, technologies, therapies and opportunities.
Visiongain’s updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your research, analyses and influence.
Please read on to explore those drug sales and find what that industry could earn in future.
Forecasts to 2025 and other analyses explain and predict the antithrombotics market
Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.
That study also shows 84 tables, 69 charts and two interviews  with authorities in that field.
There you assess the future of treatments to prevent blood clotting and dissolve blood clots. And the following sections explain what our new investigation gives.
Forecasting of that world market and its segments – what does the future hold?
What’re the secrets of that industry's progress? Discover in our report overall world revenue prediction to 2025 for antithrombotic medicines, with discussions.
Also find individual revenue forecasts to 2025 for eight therapeutic submarkets at world level:
- Anticoagulants
- Antiplatelet agents
- Fibrinolytic treatments.
And you get forecasts for these anticoagulant drug classes:
- Direct factor Xa inhibitors
- Heparins
- Direct thrombin inhibitors
- Vitamin K antagonists
- Other therapeutics (grouped forecast).
There assess outlooks for sales expansion, hearing where you could profit. You investigate competition and rising sales. And you examine the clinical and commercial possibilities.
And also find top medicines’ potentials.
Predictions of leading products’ sales
How will individual drugs perform to 2025 at world level? Our study forecasts revenues of 14 brands. Assess products, including these:
- Plavix
- Lovenox
- Xarelto
- Pradaxa
- Activase
- Effient
- Aspirin Cardio
- Pletal.
There you find drugs and years with highest predicted sales. You also examine competitors. So discover what’s happening, understanding challenges, trends, competition and opportunities.
That work also shows geographical revenue predictions.
National markets – what outlooks for revenues?
In developed and developing countries, many opportunities for producers and sellers of antithrombotic medicines will occur from 2015 to 2025. See where, how and what’s possible.
Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
- United States (US)
- Japan
- EU leaders – Germany, France, the UK, Italy and Spain (EU5)
- BRIC nations – Brazil, Russia, India and China.
There you explore progress, needs and opportunities. What events change that market? Our work shows you, discussing trends and demands.
Events affecting developers, producers and sellers of those cardiovascular medicines
That report also explains issues, forces and events affecting the antithrombotics industry and market from 2015, including these:
- Progress and outlooks for preventing and treating thrombosis, pulmonary embolism, stroke, acute coronary syndrome (ACS) and related cardiovascular disorders
- Expanding patient populations stimulating demand for those blood regulating medicines
- Competition from generics and biosimilars, including discussion of regulatory guidelines for biosimilar low-molecular-weight heparin (LMWH).
And these issues, among others:
- Governmental healthcare spending and effects on that market’s performance<

Table Of Contents

Antithrombotic Drugs: World Industry and Market Prospects 2015-2025
Table of Contents
1. Report Overview
1.1 Overview of the World Market for Antithrombotic Drugs
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Glossary of Abbreviations
2. Blood Clotting: Mechanisms, Disorders and Current Treatments
2.1 Understanding Haemostasis and Coagulation
2.2 What is Thrombosis
2.3 Complications of Thrombosis
2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
2.4 Antithrombotic Drug Treatment
3. Antithrombotic Drugs: World Market 2015-2025
3.1 The World Antithrombotic Drug Market in 2013 and 2014
3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2014-2025
3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
3.3.1 An Increasing Patient Population Drives Market Growth
3.3.2 Intense Competition from Generics Threatens to Restrain the Market
3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025
3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.6 Anticoagulant Drugs: Leading the Market from 2014 Onwards
3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential
3.6.2 Heparins: Second-Leading Anticoagulant Class in 2013
3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2013 and 2014
3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2014
3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market
4. Leading Products in the Market: Prospects, 2015-2025
4.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic Competition
4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2019 and 2025
4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2025?
4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?
4.4.1 Branded Competition for Plavix?
4.5 Lovenox: Biosimilar Competition in the EU is Expected
4.6 Xarelto: Leading Antithrombotic of 2014
4.7 Pradaxa's Continued Growth in 2014
4.8 Activase Leads the Fibrinolytics Market, With Little Competition
4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix
4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US
4.14 Sandoz's Enoxaparin Sodium: Revenue Forecast 2014-2025
4.15 Fragmin Faces Rivalry from Generic Competition to Lovenox
4.16 Brilinta/Brilique: Investigation Closed in 2014
4.17 Eliquis: Will Late Entry to the Market Affect Uptake?
4.18 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK
4.19 New Approvals in the Antithrombotic Drugs Market, 2014
4.19.1 Zontivity: The Newest Approval in Antithrombotics
4.19.2 Lixiana/Savaysa: Expansion into Other Regional Markets
5. Leading National Markets, 2014-2025
5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2013 and 2014?
5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2019 and 2025
5.3 Which National Markets Will Grow Fastest to 2025?
5.4 The US: Dominating the Antithrombotic Drug Market Through 2014-2025
5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
5.5.1 Germany Leads the EU5
5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
5.5.3 UK: Pharmaceutical Price Regulation Scheme
5.5.4 Italy's Healthcare System - Advantages Conducive to Business
5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth
5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2015-2025
5.7 Chinese Antithrombotic Drug Market Will Capture Market Share
5.8 Brazilian Antithrombotic Drug Market 2015-2025: Strong Growth as Universal Healthcare Coverage is Expanded
5.9 Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending?
5.10 Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth
6. Antithrombotic Drug Development: RandD Pipeline
6.1 The RandD Pipeline for Antithrombotic Drugs: Overview
6.2 The Antiplatelet Drug RandD Pipeline in 2014
6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
6.2.2 The Medicines Company's Kangrexel (Cangrelor) Awaits Approval
6.3 The RandD Pipeline for Anticoagulants, 2014
6.3.1 Heparins: Little RandD Activity in 2014
6.3.1.1 Will Development of Momenta's Adomiparin Continue?
6.3.1.2 The Discontinuation of Semuloparin
6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014
6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
6.3.5 Portola Pharmaceuticals' Betrixaban
6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban
6.4 The Fibrinolytics RandD Pipeline, 2014
6.4.1 Lundbeck's Desmoteplase: Failed to Meet Primary Endpoint in Phase III
6.4.2 Bharat Biotech and ThromboGenics' THR-100
6.5 The RandD Pipeline for Other Antithrombotic Drugs, 2014
6.5.1 Kyowa Hakko Kirin's KW-3357: Filed in Japan, 2014
6.5.2 Asahi Kasei Pharma America's ART 123
6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote
6.5.4 Isis Pharmaceuticals' ISIS-FXI Rx
7. Leading Companies in the Antithrombotic Drug Market
7.1 Leading Antithrombotic Drug Manufacturers in 2014
7.2 Sanofi Leads the Market, but is its Position Under Threat?
7.3 Boehringer Ingelheim Captures Market Share
7.4 Bayer Markets Two Antithrombotic Drugs
7.5 Johnson and Johnson Can Achieve Success with a Limited Product Portfolio
7.6 Genentech Will Retain Market Share
7.7 The Medicines Company's Position Will be Bolstered by the Launch of its New Drug
7.8 Eli Lilly: Market Position is Dependent on Success of Effient
7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
7.10 Pfizer: A Gradually Increasing Share of the Market
7.11 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013
8. Qualitative Analysis of the Antithrombotic Drugs Market, 2015
8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2015
8.1.1 Thrombotic Disease: Management Rather Than Cure
8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
8.2 Opportunities and Threats Facing the Market 2015-2025
8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
8.2.2 Further Development of Existing Drugs
8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
8.2.4 The Threat of Generic Competition
8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?
8.2.6 High Risk of Investment in New Drug Development
8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2015-2025
8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
8.3.3 Economic Factors
8.3.3.1 Cost Cutting in the EU and the US
8.3.3.2 Free Trade within the EU Presents Challenges
8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?
9. Research Interviews
9.1 Interview with Dr Sanjay Bhanot, PhD, Vice President of Clinical Development and Translational Medicine, Isis Pharmaceuticals, Inc.
9.1.1 Isis Pharmaceuticals Antithrombotic Drugs Pipeline
9.1.2 ISIS-FXIRx Phase II Results
9.1.3 Trends in the Antithrombotic Drug Market, 2015-2025
9.2 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil
9.2.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp
9.2.2 Heparin vs. Novel Oral Anticoagulants
9.2.3 Unmet Needs in Brazil and Worldwide
9.2.4 Trends in the Antithrombotic Drug Market
10. Conclusions from Our Study
10.1 The World Market for Antithrombotic Drugs 2015-2025
10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
10.2 The Leading National Markets 2015-2025
10.3 Trends in the Industry
10.3.1 The Market Will Recover From Plavix Decline
10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
10.3.4 High Barriers to Market Entry and a Limited Pipeline - The Implications
List of Tables
Table 1.1 Antithrombotic Drugs Market Forecast, 2014-2019
Table 1.2 Antithrombotic Drugs Market Forecast, 2019-2025
Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2013 and 2014
Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025
Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025
Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 3.9 The Warfarin Market: Companies and Year of Introduction
Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014
Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
Table 4.4 Plavix: Key Facts, 2014
Table 4.5 Selected Generic Competitors Approved by the FDA, 2014
Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.7 Lovenox: Key Facts, 2014
Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.9 Xarelto: Key Facts, 2014
Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.11 Pradaxa: Key Facts, 2014
Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.13 Activase: Key Facts, 2014
Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.15 Effient: Key Facts, 2014
Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.17 Aspirin Cardio: Key Facts, 2014
Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.19 Angiomax/Angiox: Key Facts, 2014
Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.21 Pletal: Key Facts, 2014
Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.23 Aggrenox/Asasantin: Key Facts, 2014
Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.25 Sandoz's Enoxaparin Sodium: Key Facts, 2014
Table 4.26 Sandoz's Enoxaparin Sodium: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.27 Fragmin: Key Facts, 2014
Table 4.28 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.29 Brilinta: Key Facts, 2014
Table 4.30 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.31 Eliquis: Key Facts, 2014
Table 4.32 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 4.33 Arixtra: Key Facts, 2014
Table 4.34 Zontivity: Key Facts, 2014
Table 4.35 Lixiana/Savaysa: Key Facts, 2014
Table 5.1 Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014
Table 5.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
Table 5.3 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025
Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 6.1 Selected Candidates in the Antiplatelet Drug RandD Pipeline, 2014
Table 6.2 Selected Candidates in the Heparins Pipeline, 2014
Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014
Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2014
Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014
Table 6.6 The Fibrinolytics RandD Pipeline, 2014
Table 6.7 Other Antithrombotic Drugs in Development, 2014
Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2013 and 2014
Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014
Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014
Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2014
Table 7.5 Johnson and Johnson: Antithrombotic Drug Portfolio, 2014
Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2014
Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2014
Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2014
Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014
Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2014
Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014
Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2015
Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2015-2025
Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2015-2025
List of Figures
Figure 2.1 Diagram Depicting the Coagulation Cascade
Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2013
Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Share (%), 2014
Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m),
2014-2025
Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2019
Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2025
Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2014-2025
Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025
Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2014-2025
Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2015-2025
Figure 3.11 Heparins: Revenue Forecast ($m), 2014-2025
Figure 3.12 The Heparins Market: Drivers and Restraints, 2015-2025
Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2014-2025
Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2015-2025
Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2014-2025
Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2015-2025
Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2014-2025
Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2015-2025
Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2014-2025
Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2015-2025
Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2013
Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2014
Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2019
Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2025
Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
Figure 4.6 Plavix: Revenue Forecast ($m), 2014-2025
Figure 4.7 Lovenox: Revenue Forecast ($m), 2014-2025
Figure 4.8 Xarelto: Revenue Forecast ($m), 2014-2025
Figure 4.9 Pradaxa: Revenue Forecast ($m), 2014-2025
Figure 4.10 Activase: Revenue Forecast ($m), 2014-2025
Figure 4.11 Effient: Revenue Forecast ($m), 2014-2025
Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2014-2025
Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2014-2025
Figure 4.14 Pletal: Revenue Forecast ($m), 2014-2025
Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2014-2025
Figure 4.16 Sandoz's Enoxaparin Sodium: Revenue Forecast ($m), 2014-2025
Figure 4.17 Fragmin: Revenue Forecast ($m), 2014-2025
Figure 4.18 Brilinta: Revenue Forecast ($m), 2014-2025
Figure 4.19 Eliquis: Revenue Forecast ($m), 2014-2025
Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2013
Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2014
Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2019
Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2025
Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
Figure 6.1 An Overview of the RandD Pipeline for Antithrombotic Drugs, 2014
Figure 7.1 The Top 10 Companies: Market Shares (%), 2013
Figure 7.2 The Top 10 Companies: Market Shares (%), 2014
Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2013-2025
Figure 10.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2014, 2019 and 2025
Companies Listed
Abbott Laboratories
Ablynx
Ache
Accord Healthcare
Actavis Totowa
AdvanceCor GmbH
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
Apotex
App Pharmaceuticals
ARCA biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Laboratories (subsidiary of Barr Pharmaceuticals)
Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
Bayer
Baylor College of Medicine, Houston, Texas
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Capital TEN II
Canyon Pharmaceuticals
Committee on Medicinal Products for Human Use (CHMP)
CSL Behring
Daiichi Sankyo
Dexa Medica
Diakron Pharmaceuticals
Dr. Reddy's Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fournier Pharma
Gate Pharmaceuticals
Genentech
German Institute for Quality and Efficiency in Health Care (IQWiG)
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hercules Bioventures Partners
Hoechst Marion Roussell
Hospira
Hypermarcas
Indonesia University
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson and Johnson (JandJ)
Judicial Panel on Multidistrict Litigation (US)
Kowa
Kyowa Hakko Kirin
Lee's Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Macleods Pharmaceuticals
Merck and Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mutual Pharmaceuticals
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Roxane Laboratories
Sandoz
Sanofi
ScieGen Pharmaceuticals
Sun Pharmaceuticals Indusdtries
Takeda
Taro
Teva Pharmaceutical Industries
The Medicines Company
ThromboGenics
Tianjin Medical
Tobira Therapeutics
Torrent Pharmaceuticals
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
Upjohn AB
US Department of Justice
USL Pharma
Virginia Commonwealth University
Wockhardt
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila
Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.